Replies to post #485097 on Anavex Life Sciences Corp (AVXL)

[boi568]

I think that the problem of dosing compliance in the schizo trial is not going to be an issue if the expansion of the trial size, as I expect, will remain as inpatient populations where the medical staff makes sure the patients receive the drug.

[Hoskuld]

Totally agree. I have something like a split mind when it comes to biotech investing: the part that puts the money to work is cynical and conservative and the other half of me is curious and excitable. I am very excited about the MAA and 3-71 schizophrenia trial - and still am cautious.

[frrol]

There are two main reasons for poor compliance with schizo meds: the dissociative nature of the disease itself, and the common side effects. The latter should be much less with a muscarinic modulator, if it's well tolerated. Our phase 1 went well, and hopefully acceptable GI tolerability continued in the 2a (and shows efficacy of course). We'll be finding out in a couple months, looking forward to it.

In two weeks we'll be getting 2-73's full AD OLE results, which are valuable in understanding the long term AD efficacy.